During Wednesday’s trade, following is the summary for biotech sector:

• Anthera Pharmaceuticals Inc (NASDAQ:ANTH), was the top gainer of the healthcare sector for the last trading session, and added 16.31% to the share.
• Achillion Pharmaceuticals, Inc (NASDAQ:ACHN), was among the top loser of the sector, losing -2.14% from the share, and was settled at $11.23.
• Pfizer Inc (NYSE:PFE), lately hits new 52-week high of $34.51, and was settled at $34.25.
• CAS Medical Systems Inc (NASDAQ:CASM), lately hits new 52-week low of $1.16, and was settled at $1.29.
• MannKind Corporation (NASDAQ:MNKD), was the most volatile stock, and it remained 7.03% volatile for the week and 5.42% for the month.
• Pfizer Inc (NYSE:PFE), was the most active stock for the session, and gained volume of 34.44M.
• Zoetis Inc (NYSE:ZTS), will release their earning report, before the market close today.

Insights about some real gainers from biotech segment, amid Thursday’s exchange are depicted underneath:

ArQule Inc. (NASDAQ:ARQL)’s shares inclined 14.29% and led the share to close at $1.28. ArQule’s volatility for the week is 5.85%, while for the month remained 4.31%. With recent incline, the year-to-date (YTD) performance reflected a 4.92% incline above last year. During the past month the stock gained 5.79%, bringing three-month performance to 9.40% and six-month performance to -5.88%.

ArQule Inc. (NASDAQ:ARQL), is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers.

Shares of Sangamo Biosciences Inc. (NASDAQ:SGMO), jumped nearly 9.94% and closed at $13.93, soon after Sangamo Biosciences, stated its fourth quarter and full year 2014 financial results and accomplishments. For the fourth quarter ended December 31, 2014, Sangamo stated a merged net loss of $4.3 million, or $0.06 per share, contrast to a net loss of $8.1 million, or $0.13 per share, for the same period in 2013. As of December 31, 2014, the Company had cash, cash equivalents, marketable securities and interest receivable of $226.6 million.

Sangamo Biosciences Inc. (NASDAQ:SGMO), is focused on Engineering Genetic CuresTM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing.

Synthetic Biologics Inc. (NYSEMKT:SYN), surged 7.51% to close at $1.86, soon after Synthetic Biologics, declared positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company’s investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

Synthetic Biologics Inc. (NYSEMKT:SYN), is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome.

Shares of the Advaxis, Inc. (NASDAQ:ADXS), gained 6.27% & closed at $7.46, soon after Advaxis, has reached a clinical trial partnership contract with Incyte Corporation (INCY) to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). The Phase 2 multicenter, open-label, preoperative window-study will evaluate the safety and efficacy of ADXS-HPV as a monotherapy and in combination with epacadostat in about 20 patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.

Advaxis, Inc. (NASDAQ:ADXS), is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), mounted 6.23% to close at $4.26, as Idera Pharmaceuticals, declared that it intends to offer and sell up to $75,000,000 of shares of its ordinary stock in an underwritten public offering. In connection with this offering, Idera anticipates to grant the underwriters a 30-day option to purchase additional shares of ordinary stock, equal to up to 15% of the number of shares of ordinary stock sold in the offering. All of the shares in the offering are to be sold by Idera. Idera intends to use the net proceeds from this offering, together with existing cash, cash equivalents and investments, to advance clinical development of certain of its programs. Goldman, Sachs & Co. and J.P. Morgan are acting as joint book-running managers for the offering.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare diseases. Idera’s proprietary technology involves using a Toll-like receptor (TLR) targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs.